Pharmaceutical care of patients with gestational diabetes mellitus
- 16 January 2008
- journal article
- research article
- Published by Wiley in Journal of Evaluation in Clinical Practice
- Vol. 14 (1), 131-140
- https://doi.org/10.1111/j.1365-2753.2007.00819.x
Abstract
To investigate whether the introduction of a programme of optimising drug treatment, intensive education and self-monitoring of patients diagnosed with gestational diabetes mellitus (GDM) at an early stage (<20 gestational weeks), will improve management outcomes as determined by objective measures of patient knowledge about diabetes, glycaemia control, maternal/neonatal complications, and health-related quality of life. The study was a randomized, controlled, longitudinal, prospective clinical trial performed at Al-Ain Hospital, Al-Ain, United Arab Emirates. Over an 18-month period, patients diagnosed with GDM were recruited and were randomly assigned to either an intervention or a control group, in a ratio of 3:2. Intervention patients received a structured pharmaceutical care service (including education and introduction of intensive self-monitoring) while control patients received traditional services. Patients were followed up from time of recruitment until 6 months postnatally at scheduled outpatient clinics. A range of clinical and humanistic outcome measures, including maternal and neonatal complications, were used to assess the impact of the intervention. A total of 165 patients (99 intervention, 66 control) completed the study. The intervention patients exhibited a range of benefits from the provision of the programme when compared with control group patients. Statistically significant (P < 0.05) improvements were shown in the intervention group for knowledge of diabetes, health-related quality of life (as determined by the SF36), control of plasma glucose and HbA(1c), maternal complications [e.g. decreased incidence of pre-eclampsia (5.1% vs. 16.7%), eclampsia (1.0% vs. 7.6%), episodes of severe hyperglycaemia (3.0% vs. 19.7%) and need for Caesarean section (7.1% vs. 18.2%)], and neonatal complications [e.g. decreased incidence of neonatal hypoglycaemia (2.0% vs. 10.6%), respiratory distress at birth (4.0% vs. 15.2%), hyperbilirubinaemia (1.0% vs. 12.1%) and large for gestational age (9.0% vs. 22.7%)]. The research provides clear evidence that provision of pharmaceutical care adds value to the management of GDM as exemplified by improved maternal and neonatal outcomes.Keywords
This publication has 25 references indexed in Scilit:
- A Native American Community with a 7% Cesarean Delivery Rate: Does Case Mix, Ethnicity, or Labor Management Explain the Low Rate?Annals of Family Medicine, 2003
- Self-monitoring of blood glucose in gestational diabetesThe Journal of Maternal-Fetal & Neonatal Medicine, 2002
- Maternal and perinatal outcomes in 143 Danish women with gestational diabetes mellitus and 143 controls with a similar risk profileDiabetic Medicine, 2000
- Knowledge and diabetes self-managementPatient Education and Counseling, 1996
- The MOS 36-ltem Short-Form Health Survey (SF-36): III. Tests of Data Quality, Scaling Assumptions, and Reliability Across Diverse Patient GroupsMedical Care, 1994
- Validating the SF-36 health survey questionnaire: new outcome measure for primary care.BMJ, 1992
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992
- The MOS Short-form General Health SurveyMedical Care, 1988
- Assessing clinical trials--restricted randomisation.BMJ, 1981
- The randomization and stratification of patients to clinical trialsJournal of Chronic Diseases, 1974